Viability and oxidative response of human colorectal HCT-116 cancer cells treated with visfatin/eNampt in vitro. 2015

R J Buldak, and M Gowarzewski, and L Buldak, and M Skonieczna, and M Kukla, and R Polaniak, and K Zwirska-Korczala
Medical University of Silesia, School of Medicine with the Division of Dentistry, Department of Physiology in Zabrze, Zabrze, Poland. rbuldak@gmail.com.

Visfatin/eNampt is a novel adipokine, secreted by visceral and subcutaneous fat, which could be involved in the development of obesity-associated cancer. Only few studies revealed reactive oxygen species (ROS)-dependent action of visfatin in endothelial cells, myotubes and melanoma cells. The potential pro-apoptotic properties of visfatin/eNampt in human colorectal HCT-116 cells remain unknown. The aim of the study was to examine the effects of visfatin/eNampt on cell viability along with the determination of apoptosis/necrosis extent and ROS level in HCT-116 cells. Additionally antioxidant enzymes' activities (i.e catalase (CAT), gluthatione peroxidase (GSH-Px)), and lipid peroxidation intensity in HCT-116 cells line was evaluated. Viability of HCT-116 cells was decreased after visfatin/eNampt treatment for 24 hours. The number of apoptotic cells in tested cells treated with increasing visfatin/eNampt concentrations (10, 100, 250 ng/ml) was elevated compared to untreated cells (6.4%, 9.7%, 16% vs. 3.2%; respectively). After 24 hours in the visfatin/eNampt treated group (10 - 100 ng/ml) CAT and GSH-Px activities significantly increased and this observation was accompanied by the decrease of ROS level when compared to the control group. Interestingly ROS level (using DCF detection technique) and lipid peroxidation ratio were increased in cells stimulated by visfatin/eNampt in concentration of 250 ng/ml along with the decreased activity of selected antioxidant enzymes when compared to remaining study groups, including control. We concluded that visfatin/eNampt induces decrease of cell viability and apoptosis boost in human colorectal cancer HCT-116 cells line. Visfatin/eNampt affected the level of ROS as well as antioxidant capacity, however the association of ROS level and apoptosis rate was not linear. The role for visfatin/eNampt in cancer redox status in vitro may provide a greater insight into the association between fat derived visfatin/eNampt and its endocrine action in colorectal carcinoma cells.

UI MeSH Term Description Entries
D008315 Malondialdehyde The dialdehyde of malonic acid. Malonaldehyde,Propanedial,Malonylaldehyde,Malonyldialdehyde,Sodium Malondialdehyde,Malondialdehyde, Sodium
D009336 Necrosis The death of cells in an organ or tissue due to disease, injury or failure of the blood supply.
D002374 Catalase An oxidoreductase that catalyzes the conversion of HYDROGEN PEROXIDE to water and oxygen. It is present in many animal cells. A deficiency of this enzyme results in ACATALASIA. Catalase A,Catalase T,Manganese Catalase,Mn Catalase
D002470 Cell Survival The span of viability of a cell characterized by the capacity to perform certain functions such as metabolism, growth, reproduction, some form of responsiveness, and adaptability. Cell Viability,Cell Viabilities,Survival, Cell,Viabilities, Cell,Viability, Cell
D005979 Glutathione Peroxidase An enzyme catalyzing the oxidation of 2 moles of GLUTATHIONE in the presence of HYDROGEN PEROXIDE to yield oxidized glutathione and water. Cytosolic Glutathione Peroxidase,Glutathione Lipoperoxidase,Selenoglutathione Peroxidase,Glutathione Peroxidase, Cytosolic,Lipoperoxidase, Glutathione,Peroxidase, Glutathione,Peroxidase, Selenoglutathione
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D015227 Lipid Peroxidation Peroxidase catalyzed oxidation of lipids using hydrogen peroxide as an electron acceptor. Lipid Peroxidations,Peroxidation, Lipid,Peroxidations, Lipid
D016207 Cytokines Non-antibody proteins secreted by inflammatory leukocytes and some non-leukocytic cells, that act as intercellular mediators. They differ from classical hormones in that they are produced by a number of tissue or cell types rather than by specialized glands. They generally act locally in a paracrine or autocrine rather than endocrine manner. Cytokine
D017209 Apoptosis A regulated cell death mechanism characterized by distinctive morphologic changes in the nucleus and cytoplasm, including the endonucleolytic cleavage of genomic DNA, at regularly spaced, internucleosomal sites, i.e., DNA FRAGMENTATION. It is genetically programmed and serves as a balance to mitosis in regulating the size of animal tissues and in mediating pathologic processes associated with tumor growth. Apoptosis, Extrinsic Pathway,Apoptosis, Intrinsic Pathway,Caspase-Dependent Apoptosis,Classic Apoptosis,Classical Apoptosis,Programmed Cell Death,Programmed Cell Death, Type I,Apoptoses, Extrinsic Pathway,Apoptoses, Intrinsic Pathway,Apoptosis, Caspase-Dependent,Apoptosis, Classic,Apoptosis, Classical,Caspase Dependent Apoptosis,Cell Death, Programmed,Classic Apoptoses,Extrinsic Pathway Apoptoses,Extrinsic Pathway Apoptosis,Intrinsic Pathway Apoptoses,Intrinsic Pathway Apoptosis
D017382 Reactive Oxygen Species Molecules or ions formed by the incomplete one-electron reduction of oxygen. These reactive oxygen intermediates include SINGLET OXYGEN; SUPEROXIDES; PEROXIDES; HYDROXYL RADICAL; and HYPOCHLOROUS ACID. They contribute to the microbicidal activity of PHAGOCYTES, regulation of SIGNAL TRANSDUCTION and GENE EXPRESSION, and the oxidative damage to NUCLEIC ACIDS; PROTEINS; and LIPIDS. Active Oxygen Species,Oxygen Radical,Oxygen Radicals,Pro-Oxidant,Reactive Oxygen Intermediates,Active Oxygen,Oxygen Species, Reactive,Pro-Oxidants,Oxygen, Active,Pro Oxidant,Pro Oxidants,Radical, Oxygen

Related Publications

R J Buldak, and M Gowarzewski, and L Buldak, and M Skonieczna, and M Kukla, and R Polaniak, and K Zwirska-Korczala
January 2013, International journal of molecular and cellular medicine,
R J Buldak, and M Gowarzewski, and L Buldak, and M Skonieczna, and M Kukla, and R Polaniak, and K Zwirska-Korczala
November 2015, International journal of molecular sciences,
R J Buldak, and M Gowarzewski, and L Buldak, and M Skonieczna, and M Kukla, and R Polaniak, and K Zwirska-Korczala
June 2014, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie,
R J Buldak, and M Gowarzewski, and L Buldak, and M Skonieczna, and M Kukla, and R Polaniak, and K Zwirska-Korczala
June 2022, Journal of gastrointestinal cancer,
R J Buldak, and M Gowarzewski, and L Buldak, and M Skonieczna, and M Kukla, and R Polaniak, and K Zwirska-Korczala
September 2014, European journal of histochemistry : EJH,
R J Buldak, and M Gowarzewski, and L Buldak, and M Skonieczna, and M Kukla, and R Polaniak, and K Zwirska-Korczala
July 2019, Archives of physiology and biochemistry,
R J Buldak, and M Gowarzewski, and L Buldak, and M Skonieczna, and M Kukla, and R Polaniak, and K Zwirska-Korczala
January 2008, Anticancer research,
R J Buldak, and M Gowarzewski, and L Buldak, and M Skonieczna, and M Kukla, and R Polaniak, and K Zwirska-Korczala
January 2019, Journal of Cancer,
R J Buldak, and M Gowarzewski, and L Buldak, and M Skonieczna, and M Kukla, and R Polaniak, and K Zwirska-Korczala
March 2017, Oncology letters,
R J Buldak, and M Gowarzewski, and L Buldak, and M Skonieczna, and M Kukla, and R Polaniak, and K Zwirska-Korczala
November 2023, Cureus,
Copied contents to your clipboard!